Completed PHASE1 INTERVENTIONAL 1-arm NCT00813969

Autologous Mesenchymal Stem Cell (MSC) Transplantation in MS

A Phase I Study to Assess the Feasibility, Safety, and Tolerability of Autologous Mesenchymal Stem Cell Transplantation in Patients With Relapsing Forms of Multiple Sclerosis

Sponsor: The Cleveland Clinic

Conditions Progressive Relapsing Multiple Sclerosis Relapsing-Remitting Multiple Sclerosis Secondary Progressive Multiple Sclerosis

Interventions Autologous mesenchymal stem cell transplantation

Updated 6 times since 2017 Last updated: Mar 28, 2016 Started: Mar 31, 2011 Primary completion: Jan 31, 2014 Completion: May 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Progressive Relapsing Multiple Sclerosis and Relapsing-Remitting Multiple Sclerosis and is currently completed. The Cleveland Clinic leads this study, which shows 6 recorded versions since 2011 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Mar 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

The Cleveland Clinic
University Hospitals Cleveland Medical Center

Data source: The Cleveland Clinic

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Cleveland, United States